Compare First Trust NASDAQ 100 Technology Index Fund (QTEC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ 100 Technology Index Fund vs Vertex Pharmaceuticals Incorporated — how do they compare? First Trust NASDAQ 100 Technology Index Fund trades at $329.55 (market cap $4.15B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 30.9× First Trust NASDAQ 100 Technology Index Fund's market cap, and First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ 100 Technology Index Fund for 40 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| QTEC | VRTX | |
|---|---|---|
Market Cap | $4.15B | $128.16B |
Volume | 278,646 | 806,603 |
Sector | Broad Market / Factor | Health |
52-Week High | $340.28 | $557.96 |
52-Week Low | $207.03 | $407.37 |
Typical Hold Time | 40 Days | 120 Days |
Enterprise Value | — | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QTEC trades at $335.82, down 1.31% today, with a bullish technical signal from moving averages but bearish oscillators. The ETF provides equal-weighted exposure to NASDAQ-100 technology stocks, offering diversification across software and hardware sectors. Recent analysis highlights software industry undervaluation relative to historical averages, positioning QTEC as a liquid alternative to similar funds.
The outlook remains cautiously optimistic given technology sector growth potential, though overbought RSI levels suggest near-term consolidation. Key risks include sector volatility and macroeconomic pressures on tech valuations, while institutional interest supports long-term stability.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
